Voyager Therapeutics Inc (NASDAQ:VYGR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, November 8th.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Other equities research analysts have also issued research reports about the company. Stifel Nicolaus reissued a “buy” rating and issued a $31.00 price objective (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Evercore ISI began coverage on Voyager Therapeutics in a report on Wednesday, August 16th. They issued an “outperform” rating and a $12.00 price objective for the company. Cowen Inc reissued a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, October 31st. ValuEngine lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, BidaskClub raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. Voyager Therapeutics currently has a consensus rating of “Hold” and an average price target of $26.13.
In other news, insider Bernard Ravina sold 10,980 shares of the business’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $20.33, for a total transaction of $223,223.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 38,430 shares of company stock valued at $562,890 in the last ninety days. Insiders own 8.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of VYGR. Bank of New York Mellon Corp grew its holdings in shares of Voyager Therapeutics by 15.6% during the first quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock worth $582,000 after purchasing an additional 5,952 shares in the last quarter. Wellington Management Group LLP lifted its position in Voyager Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after buying an additional 19,450 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Voyager Therapeutics by 3.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock worth $383,000 after buying an additional 1,026 shares during the last quarter. Hershey Trust Co. lifted its position in Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after buying an additional 8,921 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Voyager Therapeutics by 57.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after buying an additional 4,343 shares during the last quarter. 37.04% of the stock is owned by institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with our FREE daily email newsletter.